0 0 0 0 0 0.014426727410782 0.0485952923310555 0.0485952923310555
Sign Up Today X
Thanks for submitting the form.
Stockreport

Evolus: Chiseling Away At The Aesthetic Market [Seeking Alpha]

Evolus, Inc. (EOLS)  More Company Research Source: Seeking Alpha
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
The company is expanding its product portfolio by adding dermal fillers through exclusive agreements with Evolysse and Estyme. The market opportunity for Evolus is significant, with the neurotoxin market estimated at $3.5 billion and the dermal fillers market at $2.5 billion. Strong revenue growth, expanding product line, and imminent profitability present an attractive opportunity for a speculative small-cap stock that can potentially double. Overview Evolus ( NASDAQ: EOLS ) is a facial beauty company in the aesthetic neurotoxin market. The flagship product at this time is Jeuveau (prabotulinumtoxinA-xvfs), the first approved neurotoxin exclusively for aesthetic use. Jeuveau is a 900 kDa Recommended For You Recommended For You About EOLS Stock More on EOLS Related Stocks Trending Analysis Trending News [Read more]
IMPACT SNAPSHOT EVENT TIME: EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
EOLS alerts
from News Quantified
EOLS
NEWS
EOLS
Earnings
EOLS
Analyst Actions
EOLS
SEC Filings
Stockreport

Evolus: Chiseling Away At The Aesthetic Market [Seeking Alpha]

Evolus, Inc.  (EOLS) 
More Company Research Source: Seeking Alpha
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
The company is expanding its product portfolio by adding dermal fillers through exclusive agreements with Evolysse and Estyme. The market opportunity for Evolus is significant, with the neurotoxin market estimated at $3.5 billion and the dermal fillers market at $2.5 billion. Strong revenue growth, expanding product line, and imminent profitability present an attractive opportunity for a speculative small-cap stock that can potentially double. Overview Evolus ( NASDAQ: EOLS ) is a facial beauty company in the aesthetic neurotoxin market. The flagship product at this time is Jeuveau (prabotulinumtoxinA-xvfs), the first approved neurotoxin exclusively for aesthetic use. Jeuveau is a 900 kDa Recommended For You Recommended For You About EOLS Stock More on EOLS Related Stocks Trending Analysis Trending News [Read more]
IMPACT SNAPSHOT
EVENT TIME:
EOLS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS